1. Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
- Author
-
Liang Y, Xiao W, Peng Y, Zhang S, Dong J, Zhao J, Wang Y, Zhang M, Liu Z, and Yu B
- Subjects
- Animals, Female, Humans, Mice, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Immunity, Cellular, Immunogenicity, Vaccine, Mice, Inbred BALB C, Protein Binding, Protein Multimerization, Recombinant Fusion Proteins immunology, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins chemistry, Vaccine Development, Vaccines, Synthetic immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic chemistry, COVID-19 prevention & control, COVID-19 immunology, COVID-19 Vaccines immunology, Immunoglobulin Fc Fragments immunology, Immunoglobulin Fc Fragments chemistry, Nanovaccines, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus chemistry
- Abstract
The Fc-fused receptor binding domain (RBD-Fc) vaccine for SARS-CoV-2 has garnered significant attention for its capacity to provide effective and specific immune protection. However, its immunogenicity is limited, highlighting the need for improvement in clinical application. Nanoparticle delivery has been shown to be an effective method for enhancing antigen immunogenicity. In this study, we developed bivalent nanoparticle recombinant protein vaccines by assembling the RBD-Fc of SARS-CoV-2 and Fc-binding homo-oligomers o42.1 and i52.3 into octahedral and icosahedral nanoparticles. The formation of RBD-Fc nanoparticles was confirmed through structural characterization and cell binding experiments. Compared to RBD-Fc dimers, the nanoparticle vaccines induced more potent neutralizing antibodies (nAb) and stronger cellular immune responses. Therefore, using bivalent nanoparticle vaccines based on RBD-Fc presents a promising vaccination strategy against SARS-CoV-2 and offers a universal approach for enhancing the immunogenicity of Fc fusion protein vaccines., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF